{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T03:20:52Z","timestamp":1789701652033,"version":"4.0.1"},"reference-count":30,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>There are no standard treatments to prevent or hasten the recovery from severe conditioning-regimen\u2013induced thrombocytopenia occurring after autologous hematopoietic cell transplantation (auto-HCT). We conducted an open-label, single-arm pilot study of romiplostim, a thrombopoietin receptor agonist, to enhance platelet recovery in patients with multiple myeloma or lymphoma undergoing auto-HCT. All patients were treated weekly with romiplostim starting day\u00a0+1 after auto-HCT until the platelet count was &amp;gt;50\u00a0\u00d7 109\/L without transfusion. Compared with contemporary retrospective data from romiplostim-na\u00efve patients (N\u00a0= 853), romiplostim-treated patients (N\u00a0= 59) had a similar median number of days of grade 4 thrombocytopenia or days requiring transfusions, time to platelet engraftment, and number of platelets transfusions during the auto-HCT. However, romiplostim-treated patients had enhanced platelet recovery to normal values beginning at approximately day\u00a0+15. In matched cohort multivariable analyses, romiplostim treatment was associated with higher platelet counts by an average of 40\u00a0\u00d7 109\/L (95% confidence interval (CI) (14, 67), P\u00a0= .003) and 118\u00a0\u00d7 109\/L (95% CI [84, 152], P&amp;lt;.001) at days\u00a0+21 and\u00a0+30, respectively, compared with those of no romiplostim. Only 1 adverse event was deemed possibly attributable to romiplostim: a low-risk pulmonary embolism in a patient with multiple myeloma. In conclusion, romiplostim showed promising activity and safety after auto-HCT, but the improvement in platelet counts occurred later than the goal of shortening the duration and depth of the platelet nadir. This trial was registered at www.clinicaltrials.gov (#NCT04478123).<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007838","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T17:55:57Z","timestamp":1669053357000},"page":"1536-1544","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":14,"title":["Open-label pilot study of romiplostim for thrombocytopenia after autologous hematopoietic cell transplantation"],"prefix":"10.1182","volume":"7","author":[{"given":"Michael","family":"Scordo","sequence":"first","affiliation":[{"name":"1Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah J.","family":"Gilbert","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle M.","family":"Hanley","sequence":"additional","affiliation":[{"name":"4Department of Nursing, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8310-6684","authenticated-orcid":false,"given":"Jessica R.","family":"Flynn","sequence":"additional","affiliation":[{"name":"5Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean M.","family":"Devlin","sequence":"additional","affiliation":[{"name":"5Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linh K.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"4Department of Nursing, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josel D.","family":"Ruiz","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunjan L.","family":"Shah","sequence":"additional","affiliation":[{"name":"1Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig S.","family":"Sauter","sequence":"additional","affiliation":[{"name":"6Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Chung","sequence":"additional","affiliation":[{"name":"1Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3152-1189","authenticated-orcid":false,"given":"Heather J.","family":"Landau","sequence":"additional","affiliation":[{"name":"1Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar B.","family":"Lahoud","sequence":"additional","affiliation":[{"name":"1Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0834-7880","authenticated-orcid":false,"given":"Richard J.","family":"Lin","sequence":"additional","affiliation":[{"name":"1Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parastoo B.","family":"Dahi","sequence":"additional","affiliation":[{"name":"1Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[{"name":"1Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1944-5053","authenticated-orcid":false,"given":"Sergio A.","family":"Giralt","sequence":"additional","affiliation":[{"name":"1Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8781-903X","authenticated-orcid":false,"given":"Gerald A.","family":"Soff","sequence":"additional","affiliation":[{"name":"7General Hematology Service, Department of Medicine, University of Miami Health System\/Sylvester Cancer Center, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,4,14]]},"reference":[{"issue":"7","key":"2023042114592422500_bib1","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.bbmt.2020.03.002","article-title":"Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the american society for transplantation and cellular therapy","volume":"26","author":"Kanate","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2023042114592422500_bib2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood-2014-02-514778","article-title":"Conditioning regimens for hematopoietic cell transplantation: one size does not fit all","volume":"124","author":"Gyurkocza","year":"2014","journal-title":"Blood"},{"issue":"9850","key":"2023042114592422500_bib3","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(12)60689-8","article-title":"Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study","volume":"380","author":"Wandt","year":"2012","journal-title":"Lancet"},{"issue":"19","key":"2023042114592422500_bib4","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1212772","article-title":"A\u00a0no-prophylaxis platelet-transfusion strategy for hematologic cancers","volume":"368","author":"Stanworth","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2023042114592422500_bib5","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1182\/blood-2007-10-118372","article-title":"A\u00a0review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation","volume":"112","author":"Gajewski","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2023042114592422500_bib6","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.2017.76.1734","article-title":"Platelet transfusion for patients with cancer: American society of clinical oncology clinical practice guideline update","volume":"36","author":"Schiffer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023042114592422500_bib7","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/trf.12791","article-title":"Transfusion-related adverse events in the platelet dose study","volume":"55","author":"Kaufman","year":"2015","journal-title":"Transfusion"},{"issue":"10","key":"2023042114592422500_bib8","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/sj.bmt.1701464","article-title":"Increased platelet transfusion requirement is associated with multiple organ dysfunctions in patients undergoing hematopoietic stem cell transplantation","volume":"22","author":"Gordon","year":"1998","journal-title":"Bone Marrow Transplant"},{"issue":"24","key":"2023042114592422500_bib9","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/blood-2015-11-680744","article-title":"Thrombocytopenia is associated with a dysregulated host response in critically ill sepsis patients","volume":"127","author":"Claushuis","year":"2016","journal-title":"Blood"},{"key":"2023042114592422500_bib10","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.2147\/DDDT.S299591","article-title":"A\u00a0review of romiplostim mechanism of action and clinical applicability","volume":"15","author":"Bussel","year":"2021","journal-title":"Drug Des Dev Ther"},{"issue":"5","key":"2023042114592422500_bib11","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00520-013-2074-2","article-title":"Romiplostim for management of chemotherapy-induced thrombocytopenia","volume":"22","author":"Parameswaran","year":"2014","journal-title":"Support Care Cancer"},{"issue":"5","key":"2023042114592422500_bib12","first-page":"437","article-title":"Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia","volume":"14","author":"Al-Samkari","year":"2021","journal-title":""},{"issue":"4","key":"2023042114592422500_bib13","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.3324\/haematol.2020.251900","article-title":"A\u00a0multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies","volume":"106","author":"Al-Samkari","year":"2021","journal-title":"Haematologica"},{"issue":"31","key":"2023042114592422500_bib14","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1200\/JCO.18.01931","article-title":"Romiplostim treatment of chemotherapy-induced thrombocytopenia","volume":"37","author":"Soff","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2023042114592422500_bib15","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/sj.bmt.1705623","article-title":"Immature platelet fraction for prediction of platelet engraftment after allogeneic stem cell transplantation","volume":"39","author":"Takami","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2023042114592422500_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-03668-y","article-title":"Evaluation of the immature platelet fraction contribute to the differential diagnosis of hereditary, immune and other acquired thrombocytopenias","volume":"7","author":"Ferreira","year":"2017","journal-title":"Sci Rep"},{"issue":"8","key":"2023042114592422500_bib17","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jtct.2021.04.007","article-title":"Standardizing definitions of hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the American society for transplantation and cellular therapy transplantation and cellular therapy","volume":"27","author":"Kharfan-Dabaja","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"2023042114592422500_bib18","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/bmt.2015.308","article-title":"Venous thromboembolism in hematopoietic stem cell transplant recipients","volume":"51","author":"Chaturvedi","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2023042114592422500_bib19","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1182\/bloodadvances.2020004167","article-title":"Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma","volume":"5","author":"Dahi","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"2023042114592422500_bib20","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000510460","article-title":"Pretreatment immature platelet fraction as a surrogate of reticulated platelets predicts the response to corticosteroids in adults with immune thrombocytopenia","volume":"144","author":"Takami","year":"2021","journal-title":"Acta Haematol"},{"issue":"3","key":"2023042114592422500_bib21","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/j.bbmt.2019.12.003","article-title":"Use of thrombopoietin receptor agonists in prolonged thrombocytopenia after hematopoietic stem cell transplantation","volume":"26","author":"Mahat","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"28","key":"2023042114592422500_bib22","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update","volume":"33","author":"Smith","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2023042114592422500_bib23","doi-asserted-by":"crossref","first-page":"430.e1","DOI":"10.1016\/j.jtct.2021.02.004","article-title":"Eltrombopag for post-transplantation thrombocytopenia: results of phase ii randomized, double-blind, placebo-controlled trial","volume":"27","author":"Ahmed","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"2023042114592422500_bib24","doi-asserted-by":"crossref","first-page":"497.e1","DOI":"10.1016\/j.jtct.2021.02.033","article-title":"Phase I dose-finding, safety, and tolerability trial of romiplostim to improve platelet recovery after UCB transplantation","volume":"27","author":"Christakopoulos","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"2023042114592422500_bib25","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.bbmt.2007.04.001","article-title":"Posttransplant thrombopoiesis predicts survival in patients undergoing autologous hematopoietic progenitor cell transplantation","volume":"13","author":"Ninan","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2023042114592422500_bib26","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.bbmt.2010.11.021","article-title":"Transplanted CD34+ cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma","volume":"17","author":"Stiff","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2023042114592422500_bib27","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cyto.2003.05.001","article-title":"AMG531 stimulates megakaryopoiesis in\u00a0vitro by binding to Mpl","volume":"25","author":"Broudy","year":"2004","journal-title":"Cytokine"},{"issue":"7","key":"2023042114592422500_bib28","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1161\/ATVBAHA.119.312129","article-title":"New insights into the differentiation of megakaryocytes from hematopoietic progenitors","volume":"39","author":"Noetzli","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"2023042114592422500_bib29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/09553002.2019.1625488","article-title":"Pharmacodynamics of romiplostim alone and in combination with pegfilgrastim on acute radiation-induced thrombocytopenia and neutropenia in non-human primates","volume":"96","author":"Wong","year":"2020","journal-title":"Int J Radiat Biol"},{"key":"2023042114592422500_bib30","unstructured":"Romiplostim\n          . Highlights of Prescribing Information. Amgen; Revised 2018. Accessed 8 February 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125268s163lbl.pdf."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/8\/1536\/2045777\/blooda_adv-2022-007838-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/8\/1536\/2045777\/blooda_adv-2022-007838-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T15:50:56Z","timestamp":1682092256000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/8\/1536\/493296\/Open-label-pilot-study-of-romiplostim-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,14]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,4,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007838","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,14]]}}}